Becton, Dickinson and Company $BDX Stock Holdings Increased by Handelsbanken Fonder AB

Handelsbanken Fonder AB boosted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 32.7% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 170,572 shares of the medical instruments supplier’s stock after purchasing an additional 42,040 shares during the period. Handelsbanken Fonder AB’s holdings in Becton, Dickinson and Company were worth $25,813,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Becton, Dickinson and Company by 4.4% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after purchasing an additional 26,671 shares in the last quarter. Cooke & Bieler LP raised its stake in Becton, Dickinson and Company by 27.2% in the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after purchasing an additional 240,673 shares in the last quarter. KLP Kapitalforvaltning AS lifted its position in Becton, Dickinson and Company by 61.2% during the fourth quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier’s stock valued at $33,493,000 after purchasing an additional 65,500 shares during the last quarter. Finally, Luxor Capital Group LP purchased a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $38,874,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 1.0%

Shares of BDX opened at $183.14 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm has a market cap of $50.46 billion, a price-to-earnings ratio of 55.16, a PEG ratio of 12.79 and a beta of 0.19. The firm has a 50 day moving average price of $156.55 and a 200-day moving average price of $161.69. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating the consensus estimate of $3.14 by $0.09. The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.84%. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the firm earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Michael David Garrison sold 1,100 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares of the company’s stock, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 7,627 shares of company stock worth $1,206,549. Company insiders own 0.40% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on BDX shares. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research report on Monday, July 6th. Piper Sandler upped their target price on shares of Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Bank of America reduced their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research note on Friday, June 12th. TD Cowen raised their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Citigroup upped their price objective on Becton, Dickinson and Company from $198.00 to $204.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $185.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.